Los Angeles, CA — August 6, 2025 — Leads & Copy — Immix Biopharma, Inc. announced updates to its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. The company is developing NXC-201 with a “digital filter” that filters out non-specific activation. ImmixBio plans to release forthcoming clinical data at upcoming scientific forums and is on track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis.
The company plans to partner-out other serious disease programs, according to Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer, added that partnerships could fuel the path to NEXICART-2 BLA submission for FDA approval and future development programs.
Immix Biopharma (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832). Interim results were presented at ASCO 2025. NXC-201 has been granted Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
irteam@immixbio.com
Source: Immix Biopharma, Inc.
